Catalog No.
Product Name
Application
Product Information
Citations
- Deltonin is a steroidal saponin isolated from *Dioscorea zingiberensis*, exhibiting notable antitumor activity. It exerts its effects by inhibiting the activation of key survival and proliferation pathways, specifically ERK1/2 and AKT signaling. Through this dual inhibition, Deltonin suppresses tumor cell growth and promotes apoptosis, making it a promising candidate for further investigation in cancer research and therapeutic development.
-
PPAR agonist
Lobeglitazone is a novel thiazolidinedione-class compound and an orally active dual agonist of peroxisome proliferator-activated receptors (PPARs), with EC₅₀ values of 137.4 nM for PPARγ and 546.3 nM for PPARα. In addition to its metabolic effects, Lobeglitazone functions as an inhibitor of multiple pro-inflammatory and pro-fibrotic signaling pathways, including ERK, JNK, Smad, and NF-κB. Lobeglitazone exhibits a broad range of pharmacological activities, including anti-inflammatory, anti-diabetic, anti-fibrotic, and anti-atherosclerotic effects. These properties make it a promising candidate for therapeutic research in metabolic syndrome, type 2 diabetes, cardiovascular disease, and fibrosis-related conditions. -
Endogenous Metabolite
Gamma-linolenic acid (γ-linolenic acid, GLA) is an orally active omega-6 unsaturated fatty acid with broad pharmacological activities. It exhibits anti-inflammatory effects by inhibiting the NF-κB signaling pathway and suppressing the phosphorylation of ERK1/2 and JNK, key mediators of inflammatory responses. GLA also induces apoptosis in cancer cells, contributing to its anticancer potential. Additionally, it possesses antioxidant properties and has been shown to improve memory function, suggesting neuroprotective benefits. These multifunctional effects position gamma-linolenic acid as a promising compound for research in inflammation, oncology, and neurological disorders. -
PDE4/NF-κB inhibitor
Sappanone A is an orally active homoisoflavone isolated from Caesalpinia sappan L., exhibiting notable anti-inflammatory and antioxidant properties. It functions as an inhibitor of phosphodiesterase 4 (PDE4) and NF-κB, key regulators of inflammatory signaling. Additionally, Sappanone A activates the Nrf2 pathway, leading to increased expression of the cytoprotective enzyme heme oxygenase-1 (HO-1). Sappanone A also inhibits RANKL-induced osteoclastogenesis, suggesting potential benefits in bone metabolism disorders. With its multifaceted bioactivity, Sappanone A holds significant promise for research in inflammation-related diseases, cardiovascular conditions, and bone health. -
phospholipase A2/HDAC2 inhibitor
Rhamnetin is a naturally occurring flavonoid and quercetin derivative found in *Coriandrum sativum*. It functions as an inhibitor of secretory phospholipase A₂ and histone deacetylase 2 (HDAC2), contributing to its broad pharmacological profile. Rhamnetin exhibits notable antitumor, antioxidant, and anti-inflammatory activities, making it a promising compound for research in cancer, oxidative stress-related conditions, and inflammatory diseases. -
COX-1/HDAC/Tyrosinase Inhibitor
Gnetol is a bioactive phenolic compound isolated from the root of *Gnetum montanum* with diverse pharmacological properties. It potently inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 0.78 μM and exhibits histone deacetylase (HDAC) inhibitory activity. Gnetol is also a strong tyrosinase inhibitor, with an IC₅₀ of 4.5 μM against murine tyrosinase, leading to suppression of melanin biosynthesis. In addition to its antioxidant, antiproliferative, anticancer, and hepatoprotective effects, Gnetol modulates metabolic enzymes in a concentration-dependent manner, including α-amylase, α-glucosidase, and adipogenesis pathways, making it a promising candidate for research in oncology, dermatology, and metabolic disorders. -
Endogenous Metabolite
Triacetin (Glyceryl triacetate) is an orally active synthetic triester of glycerol and acetic acid that serves as a bioavailable source of acetate. It freely crosses the blood–brain barrier and cellular membranes, making it particularly effective in targeting central nervous system malignancies. In glioma cells, Triacetin increases intracellular acetate levels, promotes histone acetylation, and induces cell cycle arrest and apoptosis. Additionally, Triacetin enhances the chemotherapeutic efficacy of Temozolomide (TMZ), supporting its potential as an adjuvant in glioma treatment strategies. -
PDE6D/IKZF1/IKZF3/CK1α Degrader
FPFT-2216 is a “molecular glue” degrader that facilitates the proteasomal degradation of multiple target proteins, including phosphodiesterase 6D (PDE6D), zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), as well as casein kinase 1α (CK1α). By promoting selective ubiquitination through E3 ligase recruitment, FPFT-2216 modulates key regulatory pathways and holds promise for research in oncology and inflammatory diseases. -
Ferroptosis inhibitor
SRS11-92 is a potent ferroptosis inhibitor and structural analogue of Ferrostatin-1 (Fer-1). It effectively blocks Erastin-induced ferroptotic cell death in HT-1080 human fibrosarcoma cells, with an EC₅₀ of 6 nM. SRS11-92 serves as a valuable tool for studying ferroptosis and its therapeutic modulation in oxidative stress-related diseases and cancer. -
FFAR3 agonist
AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3, also known as GPR41), with an IC₅₀ of 117 nM. It demonstrates anti-inflammatory, antitumor, and antidiabetic activities. AR420626 improves neurogenic diarrhea by modulating neural pathways mediated by nicotinic acetylcholine receptors (nAChRs). In cancer models, it suppresses the growth of HepG2 xenografts and inhibits hepatoma cell proliferation through apoptosis induction. Additionally, AR420626 mitigates allergic asthma and eczema and enhances glucose uptake by activating FFAR3-mediated Ca²⁺ signaling, offering potential therapeutic benefits in metabolic disorders such as diabetes. -
PROTAC NCOA4 degrader
PROTAC NCOA4 Degrader-1 (Compound V3) is a highly potent PROTAC targeting NCOA4, with a DC₅₀ of 3 nM in HeLa cells. It functions as a ferroptosis inhibitor by reducing NCOA4 levels and lowering intracellular ferrous iron (Fe²⁺) concentrations. PROTAC NCOA4 Degrader-1 has demonstrated protective effects in a CCl₄-induced acute liver injury model, making it a valuable tool for studying ferroptosis and liver disease therapeutics. -
PROTAC HK2 Degrader
C-02 is a PROTAC molecule composed of the hexokinase inhibitor lonidamine linked to the cereblon ligand thalidomide. It selectively degrades hexokinase 2 in 786-O and PANC-1 cells at 20 µM. C-02 exhibits cytotoxicity across multiple cancer cell lines, with IC₅₀ values of 34.07 µM (786-O), 5.08 µM (4T1), 31.53 µM (PANC-1), 6.11 µM (HGC-27), and 21.65 µM (MCF-7), supporting its use in cancer metabolism research. -
PROTAC SGK3 degrader
SGK3-PROTAC1 is a PROTAC molecule designed to selectively degrade SGK3 by linking the 308-R SGK inhibitor to the VHL-binding ligand VH032. Through recruitment of the VHL E3 ligase, SGK3-PROTAC1 induces proteasomal degradation of SGK3, providing a targeted approach for studying SGK3 function in cellular signaling and disease. -
Halo PROTAC degrader
HaloPROTAC-E is a potent and selective PROTAC designed to degrade Halo-tagged endoplasmic reticulum-localized proteins, including SGK3 and VPS34, with a DC₅₀ of 3–10 nM. It effectively induces degradation of endogenous VPS34 complexes (VPS34, VPS15, Beclin1, and ATG14) when Halo-tagged, leading to inhibition of autophagy. HaloPROTAC-E is a valuable tool for conditional protein degradation and autophagy research. -
MAO/LSD1 Inhibitor
Tranylcypromine hemisulfate is an irreversible, nonselective inhibitor of monoamine oxidase (MAO) and also acts as a lysine-specific demethylase 1 (LSD1) inhibitor. This compound demonstrates notable antidepressant effects and is utilized in the treatment of depression. Additionally, tranylcypromine hemisulfate has been shown to suppress lesion growth and alleviate generalized hyperalgesia in mouse models of induced endometriosis, making it a valuable tool for research in both psychiatric and pain-related studies. -
Anti-inflammatory Agent
Delmitide (RDP58) is an orally active d-isomer decapeptide that functions as a potent anti-inflammatory agent. It effectively inhibits the production of pro-inflammatory cytokines such as TNF-α, IFN-γ, and interleukin (IL)-12, while also up-regulating heme oxygenase 1 activity. Delmitide is valuable for research applications focused on ulcerative colitis and other inflammatory conditions. -
PDE Inhibitor
Theophylline sodium acetate functions as a potent phosphodiesterase (PDE) inhibitor, specifically targeting PDE3 to promote the relaxation of airway smooth muscle. It also acts as an adenosine receptor antagonist and histone deacetylase (HDAC) activator, contributing to its anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation to the nucleus. Additionally, Theophylline sodium acetate is known to induce apoptosis, making it a valuable reagent for research on asthma and chronic obstructive pulmonary disease (COPD). -
PDE4 Inhibitor
PDE4-IN-10 is a selective phosphodiesterase 4 (PDE4) inhibitor, exhibiting an IC50 of 7.01 μM for the PDE4B isoform. This compound demonstrates significant biological activity by inhibiting TNF-α production and exhibits microsomal stability, making it suitable for various in vitro applications. PDE4-IN-10 is a valuable tool for research aimed at understanding inflammatory processes and developing therapeutic strategies for related diseases. -
Endogenous Metabolite
Phosphocreatine disodium is an endogenous metabolite primarily recognized for its involvement in energy metabolism within vertebrate skeletal muscles. This compound enhances antioxidant activity and activates the TAK1 pathway, offering cardioprotective effects. Additionally, it normalizes mitochondrial function and mitigates oxidative stress through the Akt-mediated Nrf2/HO-1 signaling pathway, while also providing renal protection by suppressing apoptosis and reactive oxygen species generation via the ERK-mediated Nrf2/HO-1 pathway. Phosphocreatine disodium is valuable for research investigating cellular energy dynamics and oxidative stress responses. -
Endogenous Metabolite
Creatine monohydrate, an endogenous metabolite, primarily functions as a critical regulator of cellular energy homeostasis. Its key biological activity includes the enhancement of ATP synthesis, which is essential for energy production in muscle and brain tissues. This compound is widely utilized in research related to energy metabolism, neuroprotection, and athletic performance enhancement. -
HSP90 Inhibitor
SST0116CL1 free base is a potent inhibitor of the heat shock protein 90 (HSP90) with an IC50 of 0.21 μM. It selectively binds to the ATP binding pocket of HSP90, disrupting its chaperone activity and leading to the degradation of client proteins such as EGFR, CDK4, and AKT. SST0116CL1 free base has demonstrated significant antiproliferative effects, including the degradation of Her2 in BT-474 cells (IC50: 0.2 μM), and is applicable in the study of leukemia, gastric cancer, and ovarian carcinoma. -
Endogenous Metabolite
Phosphocreatine dipotassium is an endogenous metabolite that serves as a critical energy reservoir in vertebrate skeletal muscles. It enhances antioxidant activity and activates the TAK1 pathway, providing cardioprotective effects. Furthermore, phosphocreatine normalizes mitochondrial function and mitigates oxidative stress via the Akt-mediated Nrf2/HO-1 pathway. It also offers renal protection by suppressing apoptosis and reactive oxygen species generation through the ERK-mediated Nrf2/HO-1 pathway, making it a valuable reagent for studies in cellular metabolism and oxidative stress. -
HSP90 Inhibitor
SST0116CL1 is a potent HSP90 inhibitor with an IC50 of 0.21 μM. This compound binds to the ATP binding pocket of HSP90, disrupting its chaperone function and promoting the degradation of client proteins such as EGFR, CDK4, and AKT. SST0116CL1 demonstrates antiproliferative activity and is effective in reducing Her2 levels in BT-474 cells (IC50: 0.2 μM). It is suitable for research applications involving leukemia, gastric carcinoma, and ovarian carcinoma. -
PKM2/PDK1 Inhibitor
PKM2/PDK1-IN-1 is a dual inhibitor targeting pyruvate kinase M2 (PKM2) and pyruvate dehydrogenase kinase 1 (PDK1). It demonstrates significant biological activity by inhibiting the proliferation of non-small cell lung cancer (NSCLC) cells and inducing apoptosis. This compound promotes intercellular reactive oxygen species (ROS) production and modulates apoptotic proteins, engaging both mitochondrial and death receptor pathways in cancer cell death. Its unique mechanism makes it a valuable tool for research in cancer biology and therapeutic development. -
HSP90 Inhibitor
DDO-6600 is a covalent inhibitor of Hsp90, targeting its interaction with the co-chaperone protein Cdc37. This mechanism leads to the degradation of client kinases, including AKT, CDK4, and c-Raf, and exhibits potent inhibitory activity against various cancer cell lines. Notably, DDO-6600 reduces migration and invasion of HCT-116 cells while inducing cell cycle arrest and apoptosis. In vivo studies demonstrate its significant efficacy in inhibiting tumor growth in the HCT-116 xenograft model, making it a valuable tool for research in colorectal cancer. -
HSP90 Inhibitor
HVH-2930 is a potent inhibitor of heat shock protein 90 (HSP90), demonstrated to significantly impair the viability of BT474 and JIMT-1 breast cancer cell lines, with IC50 values of 6.86 μM and 4.42 μM, respectively. This compound mediates its effects by downregulating critical HSP90 client proteins, including HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin. In preclinical studies, HVH-2930 has shown notable antitumor efficacy in mouse models and possesses favorable pharmacokinetic properties in vivo, positioning it as a valuable tool for cancer research focused on HSP90 inhibition. -
Endogenous Metabolite
Creosol (2-Methoxy-4-methylphenol) is an endogenous metabolite that serves as a significant chemical intermediate and a potential biofuel derived from lignocellulosic biomass. Its ability to penetrate the blood-brain barrier enhances its relevance in neurobiological research and metabolic studies. Creosol may be utilized in exploring biochemical pathways and developing greener energy alternatives, making it a valuable tool for scientific investigations in these areas. -
HSP90AB1/EEF1A1 Inhibitor
Gamendazole is a selective inhibitor targeting HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A). It effectively binds to the C-terminal nucleotide binding pocket of HSP90, leading to the downregulation of key clients such as AKT1 and ERBB2 while stabilizing the HSP90 heterocomplex. Additionally, Gamendazole specifically inhibits the actin bundling activity of EEF1A1 without affecting its ribosomal functions, making it a valuable tool for studying protein interactions and mechanisms. Furthermore, Gamendazole exhibits antispermatogenic properties, suggesting potential applications in developing reversible non-hormonal male contraceptives. -
Endogenous Metabolite
Phosphocreatine disodium hydrate is an endogenous metabolite primarily involved in energy metabolism within vertebrate skeletal muscles. This compound enhances antioxidant activity and activates the TAK1 pathway, contributing to cardiac protection. Additionally, it normalizes mitochondrial function and mitigates oxidative stress through the Akt-mediated Nrf2/HO-1 pathway. Phosphocreatine disodium hydrate also exhibits renal protective effects by suppressing apoptosis and reactive oxygen species generation via the ERK-mediated Nrf2/HO-1 pathway. -
PPAR δ/γ Agonist
ZLY06 is a dual agonist of peroxisome proliferator-activated receptors (PPAR) δ and γ, exhibiting EC50 values of 341 nM and 237 nM, respectively. This compound promotes hepatic lipid accumulation through the inhibition of AKT1 phosphorylation, leading to the upregulation of CD36. Furthermore, ZLY06 enhances glucose and lipid metabolism while preventing weight gain, and mitigates fatty liver by facilitating β-oxidation of fatty acids and suppressing hepatic lipogenesis. It is valuable for research in metabolic disorders and fatty liver disease. -
RXRa Antagonist
K-8012 is a potent RXRa antagonist, with an IC50 of approximately 9.2 μM for inhibiting 9-cis-retinoic acid-induced Gal4-RXRa-LBD trans-activation. This compound demonstrates enhanced anticancer activity compared to sulindac in an RXRa-dependent manner. K-8012 effectively inhibits the tRXRa-mediated PI3K/AKT signaling pathway, promoting apoptosis and suppressing AKT activation by disrupting the interaction between tRXRa and p85α. These properties make K-8012 valuable for research in cancer biology and signaling pathways. -
Antiinflammatory Agent
Ethyl linoleate, an unsaturated fatty acid derivative, acts as an anti-inflammatory agent by inhibiting the Akt/GSK3β/β-catenin signaling pathway and blocking NF-κB activation. Additionally, it induces heme oxygenase-1 and inhibits tyrosinase, contributing to its whitening and anti-inflammatory properties. Ethyl linoleate promotes absorption of compounds and has notable implications for atherosclerosis research. Its applications extend to the study of various inflammatory diseases and cosmetic formulations. -
Angiotensin Receptor Inhibitor
YS-49 monohydrate is a selective angiotensin receptor inhibitor, primarily targeting the angiotensin II pathway. This compound effectively reduces angiotensin II-stimulated proliferation of vascular smooth muscle cells by inducing heme oxygenase-1, offering potential therapeutic insights for cardiovascular research. Additionally, as an isoquinoline alkaloid, YS-49 demonstrates significant positive inotropic effects through the activation of cardiac β-adrenoceptors, making it a valuable reagent for studies involving cardiac function and vascular biology. -
hMAO-A Inhibitor
Osthenol is a reversible and selective competitive inhibitor of human monoamine oxidase A (hMAO-A), with an IC50 of 0.74 μM and a Ki of 0.26 μM. This compound exhibits both antifungal and antibacterial properties, while also modulating the oxidative deamination of monoamine neurotransmitters. Additionally, Osthenol has been shown to inhibit the PI3K/AKT signaling pathway, leading to apoptosis in colon cancer cells, G1 phase cell cycle arrest, and reduced cell proliferation. Its applications are significant in the study of neurological disorders and cancer, particularly in targeting MAO-A for depression and investigating mechanisms in colon cancer. -
Endogenous Metabolite
D-Allose is an endogenous metabolite that exhibits significant antitumor activity against various cancer cell types. It functions by scavenging reactive oxygen species (ROS) and mitigating oxidative stress damage. Furthermore, D-Allose demonstrates anti-inflammatory and neuroprotective effects through the inhibition of the TLR4/PI3K/AKT signaling pathway. Additionally, it possesses antihypertensive, cryoprotective, and anti-osteoporotic activities, making it a valuable candidate for diverse research applications in cancer, inflammation, and metabolic disorders. -
Stable Isotope
Iminostilbene-d10 is a deuterated derivative of Iminostilbene, functioning as a stable isotope that aids in biological tracking and analytical studies. This compound serves as a precursor for carbamazepine and acts as an orally active inhibitor of pyruvate kinase M2 (PKM2) and cyclooxygenase-2 (COX2). Iminostilbene-d10 is instrumental in research exploring inflammation regulation, cardiovascular diseases, and immune-related disorders, as it modulates cytokine release and mitigates macrophage-mediated inflammatory responses. Its unique properties make it a valuable tool for studying myocardial ischemia/reperfusion injury and related pathways. -
PDE Inhibitor
Theophylline L-lysine is a soluble derivative of Theophylline that primarily acts as a phosphodiesterase (PDE) inhibitor. It effectively inhibits PDE3 activity, which leads to relaxation of airway smooth muscle and exhibits anti-inflammatory properties through the enhancement of IL-10 levels and the inhibition of NF-κB nuclear translocation. Additionally, Theophylline L-lysine induces apoptosis, making it a valuable compound for research applications in asthma and chronic obstructive pulmonary disease (COPD). -
PDE4 PROTAC Degrader
PROTAC PDE4 degrader-1 is a selective and orally active degrader targeting phosphodiesterase 4 (PDE4). It exhibits a DC50 of 41.98 μM and effectively inhibits the secretion of pro-inflammatory cytokines such as TNF-α and IL-6. This compound demonstrates significant potential in alleviating pulmonary inflammation in LPS-induced acute lung injury models, making it a valuable tool for studying inflammatory diseases and therapeutic interventions. -
PDE4 Inhibitor
AN-2898 is a selective phosphodiesterase 4 (PDE4) inhibitor with an IC50 of 0.027 μM, demonstrating significant potency over other phosphodiesterase enzymes, including PDE1A, PDE2A, and PDE3A. It effectively inhibits PDE4 subtypes such as PDE4B1, PDE4A1A, and PDE4D2. AN-2898 significantly reduces the production of pro-inflammatory cytokines including TNF-α, IL-2, IFN-γ, IL-5, and IL-10, making it a valuable reagent for research applications in mild to moderate atopic dermatitis and psoriasis. -
PDE4 Inhibitor
LY2775240 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor, demonstrating significant inhibitory activity against PDE4A, PDE4B, and PDE4D with IC₅₀ values of 0.09 nM and 0.14 nM for the latter two, as well as an IC₅₀ of 2.4 nM for PDE4C. This compound effectively reduces TNFα production during immune activation, making it valuable for studies investigating inflammatory conditions. LY2775240 is particularly relevant for research focused on psoriasis, as evidenced by its efficacy in lowering TNFα levels in rodent and cynomolgus monkey models. -
FASN/SCD Inhibitor
FASN/SCD-IN-1 is a potent inhibitor of Fatty Acid Synthase (FASN) and Stearoyl-CoA Desaturase (SCD), derived from Silybin. This orally active compound exhibits significant biological activities, including the inhibition of lipid deposition and reduction of FASN and SCD transcription levels. Additionally, FASN/SCD-IN-1 demonstrates antioxidant, anti-inflammatory, and anti-fibrotic properties, with notable hepatoprotective effects in rat models of acute liver injury. Its ability to ameliorate pathological features such as steatosis, inflammation, and fibrosis in mouse models of myeloproliferative steatohepatitis (MASH) makes it a valuable tool for exploring mechanisms underlying MASH-related liver conditions. -
PPARγ Activator
12-Nitrolinoleate is a potent peroxisome proliferator-activated receptor γ (PPARγ) activator derived from linoleic acid through nitration. It effectively induces PPARγ-dependent gene expression in MCF-7 cells, demonstrating an EC50 of 0.045 μM. Additionally, 12-Nitrolinoleate exhibits anti-inflammatory properties by inhibiting NF-κB transcription in RAW 264.7 cells, along with reducing levels of pro-inflammatory cytokines such as IL-6, TNF-α, and CCL2 in response to LPS stimulation. This compound is valuable for research applications focused on metabolic regulation and inflammation. -
PDE4 Inhibitor
ASP9831 is an orally active phosphodiesterase type 4 (PDE4) inhibitor. It effectively inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-α) production, demonstrating notable anti-inflammatory properties. This compound is valuable for research applications centered on fatty liver disease and related inflammatory conditions. -
Endogenous Metabolite
rel-(1S,2R)-Dihydro bupropion is a metabolite of bupropion that primarily influences the immune response by promoting endogenous interleukin-10 (IL-10) production while inhibiting Th1 cytokines such as interleukin-12 (IL-12) and tumor necrosis factor-alpha (TNF-α). This transition in immune response from Th1 to Th2 underscores its biological activity in modulating inflammatory conditions. rel-(1S,2R)-Dihydro bupropion serves as a valuable tool in research focused on understanding and addressing immune-related disorders. -
PDE4 Inhibitor
Revamilast is an orally active phosphodiesterase-4 (PDE4) inhibitor with a reported IC50 of 3 nM. This compound effectively inhibits the production of tumor necrosis factor-alpha (TNF-α), making it a valuable tool for research into inflammatory conditions. Applications include studies related to rheumatoid arthritis, plaque psoriasis, asthma, and other related inflammatory diseases. -
PDE4 Inhibitor
PDE4-IN-15 is a selective inhibitor of phosphodiesterase 4 (PDE4) with an IC50 value of 0.17 μM. This compound demonstrates notable anti-TNF-α activity, exhibiting an EC50 of 0.19 μM, which is significant for inflammatory research. Additionally, PDE4-IN-15 shows good skin permeability, making it suitable for studies involving topical administration and localized therapeutic applications. -
PDE Inhibitor
Theophylline sodium glycinate is a potent phosphodiesterase (PDE) inhibitor with significant effects on airway smooth muscle relaxation. It acts primarily by inhibiting PDE3, which contributes to its anti-inflammatory properties through the upregulation of IL-10 and the inhibition of NF-κB translocation into the nucleus. Additionally, Theophylline sodium glycinate has been shown to induce apoptosis. This reagent is valuable for research applications related to asthma and chronic obstructive pulmonary disease (COPD). -
Anti-inflammatory/Anti-tumor/Anti-mite Agent
2′-Hydroxy-5′-methoxyacetophenone is an acetophenone derivative that modulates inflammatory responses primarily through inhibition of the NF-κB signaling pathway. This compound demonstrates significant anti-tumor properties, particularly against ovarian cancer, and exhibits acaricidal activity. Additionally, it effectively inhibits enzymes such as α-amylase, collagenase, and aldose reductase with IC50 values of 0.928 μM, 3.264 μM, and 20.046 μM, respectively, indicating its potential in diabetes research. -
PDE-4 Inhibitor
Apremilast-d5 is a deuterated analog of Apremilast, a potent inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC50 of 74 nM. This compound effectively reduces TNF-α release in response to lipopolysaccharide (LPS) stimulation, exhibiting an IC50 of 104 nM. Apremilast-d5 is valuable for research applications related to inflammatory diseases and the modulation of immune responses. -
Phosphodiesterase (PDE) Inhibitor
CDC801 is a potent inhibitor of phosphodiesterase 4 (PDE4) and tumor necrosis factor-α (TNF-α), with IC50 values of 1.1 μM and 2.5 μM, respectively. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into conditions associated with elevated TNF-α levels, such as autoimmune diseases and chronic inflammatory disorders. CDC801 is suitable for exploring the therapeutic potential of PDE4 inhibition and its effects on inflammatory pathways.
